These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32458510)

  • 21. Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia.
    Ozbagcivan O; Akarsu S; Nazli EC; Lebe B; Fetil E
    Ann Hematol; 2021 Jan; 100(1):293-294. PubMed ID: 32221651
    [No Abstract]   [Full Text] [Related]  

  • 22. Ibrutinib-Induced Skin Rash.
    Kirar S; Gogia A; Gupta R; Mallick S
    Turk J Haematol; 2021 Feb; 38(1):81-83. PubMed ID: 33053966
    [No Abstract]   [Full Text] [Related]  

  • 23. Refractory disseminated fusariosis by Fusarium verticillioides in a patient with acute myeloid leukaemia relapsed after allogeneic hematopoietic stem cell transplantation: a case report and literature review.
    Fanci R; Pini G; Bartolesi AM; Pecile P
    Rev Iberoam Micol; 2013 Jan; 30(1):51-3. PubMed ID: 22659590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [State of the art in invasive diseases by filamentous fungi].
    Pemán J; Quindós G
    Rev Iberoam Micol; 2014; 31(4):213-8. PubMed ID: 25449676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ibrutinib-associated necrotic nasal lesion and pulmonary infiltrates.
    Saling C; Feller F; Vikram HR
    BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33468501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.
    Marr KA; Carter RA; Crippa F; Wald A; Corey L
    Clin Infect Dis; 2002 Apr; 34(7):909-17. PubMed ID: 11880955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.
    Maffei R; Maccaferri M; Arletti L; Fiorcari S; Benatti S; Potenza L; Luppi M; Marasca R
    Blood Rev; 2020 Mar; 40():100635. PubMed ID: 31699465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular epidemiology of clinical filamentous fungi in Qatar beyond Aspergillus and Fusarium with notes on the rare species.
    Salah H; Houbraken J; Boekhout T; Almaslamani M; Taj-Aldeen SJ
    Med Mycol; 2022 Dec; 61(1):. PubMed ID: 36592959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era.
    Steingrímsson V; Gíslason GK; Þorsteinsdóttir S; Rögnvaldsson S; Gottfreðsson M; Aspelund T; Turesson I; Björkholm M; Landgren O; Kristinsson SY
    Eur J Haematol; 2021 Mar; 106(3):346-353. PubMed ID: 33211356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ibrutinib induces multiple functional defects in the neutrophil response against
    Blez D; Blaize M; Soussain C; Boissonnas A; Meghraoui-Kheddar A; Menezes N; Portalier A; Combadière C; Leblond V; Ghez D; Fekkar A
    Haematologica; 2020; 105(2):478-489. PubMed ID: 31171644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
    Brochard J; Morio F; Mahe J; Le Pape P; Guimard T; Mahe B; Leterrier M; Morrier M; Raffi F; Boutoille D
    Med Mal Infect; 2020 Nov; 50(8):742-745. PubMed ID: 32777360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging moulds: epidemiological trends and antifungal resistance.
    Miceli MH; Lee SA
    Mycoses; 2011 Nov; 54(6):e666-78. PubMed ID: 21672045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
    Gentile M; Morabito F; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Recchia AG; Varettoni M; Murru R; Chiarenza A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Fraticelli V; Vigna E; Botta C; Tripepi G; Arrigo G; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Rigolin GM; Rossi D; Di Raimondo F; Gaidano G; Polliack A; Cuneo A; Foà R; Gattei V
    Leukemia; 2021 Jan; 35(1):235-238. PubMed ID: 32286543
    [No Abstract]   [Full Text] [Related]  

  • 34. Disseminated fusariosis by Fusarium proliferatum in a patient with aplastic anaemia receiving primary posaconazole prophylaxis - case report and review of the literature.
    Ricna D; Lengerova M; Palackova M; Hadrabova M; Kocmanova I; Weinbergerova B; Pavlovsky Z; Volfova P; Bouchnerova J; Mayer J; Racil Z
    Mycoses; 2016 Jan; 59(1):48-55. PubMed ID: 26661324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
    Molica S; Gianfelici V; Levato L
    Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
    [No Abstract]   [Full Text] [Related]  

  • 36. An oral drug for chronic lymphocytic leukemia.
    Koehler A
    JAAPA; 2020 Feb; 33(2):51-53. PubMed ID: 31990837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A long-term survivor of disseminated Aspergillus and mucorales infection: an instructive case.
    Davoudi S; Anderlini P; Fuller GN; Kontoyiannis DP
    Mycopathologia; 2014 Dec; 178(5-6):465-70. PubMed ID: 25086667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discrimination of Aspergillosis, Mucormycosis, Fusariosis, and Scedosporiosis in Formalin-Fixed Paraffin-Embedded Tissue Specimens by Use of Multiple Real-Time Quantitative PCR Assays.
    Salehi E; Hedayati MT; Zoll J; Rafati H; Ghasemi M; Doroudinia A; Abastabar M; Tolooe A; Snelders E; van der Lee HA; Rijs AJ; Verweij PE; Seyedmousavi S; Melchers WJ
    J Clin Microbiol; 2016 Nov; 54(11):2798-2803. PubMed ID: 27605714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies.
    Ulusakarya A; Chachaty E; Vantelon JM; Youssef A; Tancrède C; Pico JL; Bourhis JH; Fenaux P; Munck JN
    Hematol J; 2000; 1(2):111-6. PubMed ID: 11920178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.
    Blyth CC; Gilroy NM; Guy SD; Chambers ST; Cheong EY; Gottlieb T; McGuinness SL; Thursky KA
    Intern Med J; 2014 Dec; 44(12b):1333-49. PubMed ID: 25482744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.